Anti‐VEGF antibodies, such as bevacizumab and ramucirumab, and immune checkpoint inhibitors are occasionally used for NSCLC treatment and can increase the risk of thromboembolism [30]. Here, VEGFA is linked to non-small cell lung carcinoma.